About Pluristem
Pluristem is a publicly listed company based in Haifa (Israel) founded in 2003. Off-the-shelf cell therapies are developed from human placentas. Pluristem offers products and services including 3D Cell Expansion Platforms, Cultivated Meat, and Cell-Based Coffee. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is Pluri Biotech Ltd.
Company details
Pluristem Therapeutics was founded in 2003 and is headquartered in Haifa, Israel. Operations focus on the biotechnology sector, where cell therapies are developed for various diseases using placental-derived cells. These cells are expanded through a proprietary three-dimensional technology platform to enable mass production. Known as PLX cells, they are administered without tissue matching and respond to inflammatory or ischemic signals by secreting chemokines, cytokines, and growth factors.
- Headquarters Haifa, Israel
- Stage Public
- SectorsHealthcare
- Website pluristem.com
- Social LinkedIn X YouTube
- Legal Name Pluri Biotech Ltd.
- Latest Funding Round$15M (USD), Post-IPO
May 2020
- Investorsgov.il
& 2 more
Products & Services of Pluristem
Pluristem offers a comprehensive portfolio of products and services, including 3D Cell Expansion Platforms, Cultivated Meat, and Cell-Based Coffee.
Technology for efficient cell growth in pharmaceuticals
Cell-based production of alternative proteins
Platform for producing coffee from expanded cells
Apps and channels of Pluristem
its YouTube channel Pluri has 410 subscribers and 30 videos.
Videos from Pluristem
The most watched videos on Pluristem's YouTube channel, Pluri (410 subscribers). Click a video to play it here.
More on Pluri.
Funding Insights of Pluristem
- Total Rounds 15
- Last Round Post-IPO — $15M
- First Round $1.5M
(Jan 2004)
- Investors Count 3
Latest 10 of 15 funding rounds of Pluristem with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $15M | Post-IPO | – | – | – |
| Jan 2017 | $1.97M | Grant | – | – | |
| Oct 2016 | $30M | Post-IPO | – | – | – |
| Jun 2015 | $17M | Post-IPO | – | – | – |
| Oct 2010 | $1.22M | Post-IPO | – | – | – |
| May 2010 | $250,000 | Post-IPO | – | – | – |
| Dec 2008 | $1.6M | Grant | – | – | |
| May 2007 | $13.5M | Post-IPO | – | – | |
| Apr 2006 | $3M | Post-IPO | – | – | – |
| Mar 2005 | $3.2M | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Pluristem
Pluristem has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include gov.il, European Union and Technion - Israel Institute of Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Driver license information obtaining services are provided by gov.il. | 1948 | gov.il | Jerusalem, Israel | |
Multiple engineering courses and degrees are offered by Technion college. | 1912 | technion.ac.il | Haifa, Israel |
Investor details for Pluristem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pluristem
30 people are tracked at Pluristem (15 in leadership, 15 in team).
| Name | Role | Group |
|---|---|---|
Yaky Yanay | CEO & President | Leadership |
Efrat Kaduri | Chief Business Officer | Leadership |
Ori Shalem | Director Of Operations | Leadership |
Tammy Sharon | Director Strategy And Business Operations | Leadership |
Arthur MacHlenkin | Chief Scientific Officer | Leadership |
John Dvor | Executive Vice President, North America | Leadership |
Andy Lewin | Chief Commercial Officer Pluri CDMO | Leadership |
Oren Kochavi | Chief Information Officer | Leadership |
Lior Raviv | Chief Technology Officer | Leadership |
Michal Sheleg | Vice President Clinical Development | Leadership |
Helena Shaked | Associate Director, Immunotherapy | Leadership |
Nimrod Bar Zvi | Chief Commercial Officer (ccmo) At Pluri Biotech - Cell Based Technology Platform | Leadership |
Liat Zalts | Chief Financial Officer | Leadership |
Shirley Bachar | Director Of Development | Leadership |
Anna Heymann | Head Of CDMO Project Management | Leadership |
Maya Zorea | Logistics And Warehouse Manager | Team |
Jingyi Song | Business Development Analyst | Team |
Alona Rabner | Data Lead | Team |
Alexey Rotman | IT Manager | Team |
Shai Balshin | Planning, Logistics And Warehouse Manager | Team |
10 more people are available in the full profile.
Complete people profiles for Pluristem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pluristem
4 dated milestones of Pluristem across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Pluristem is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.5M.
- Funding Latest funding round, Post-IPO, of $15.0M.
Web traffic of Pluristem
Websites that share an audience with Pluristem (pluristem.com).
Websites whose visitors overlap most with Pluristem. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stemcellsinc.com | 100% | View details | |||
isletmedical.com | isletmedical.com | 78% | – | ||
| primogenix.com | 78% | View details | |||
| cognatebioservices.com | 78% | View details | |||
celle.com | celle.com | 78% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Pluristem
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pluristem
Complete news archive for Pluristem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pluristem
Pluristem was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Pluristem is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Pluristem Therapeutics was founded in 2003 and is headquartered in Haifa, Israel. Operations focus on the biotechnology sector, where cell therapies are developed for various diseases using placental-derived cells. These cells are expanded through a proprietary three-dimensional technology platform to enable mass production. Known as PLX cells, they are administered without tissue matching and respond to inflammatory or ischemic signals by secreting chemokines, cytokines, and growth factors.
Pluristem offers 3D Cell Expansion Platforms, Cultivated Meat, and Cell-Based Coffee.
Pluristem has 3 investors. Key investors include gov.il, European Union, and Technion - Israel Institute of Technology.
Pluristem operates through Pluri Biotech Ltd..